Business Standard

Friday, December 20, 2024 | 10:58 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla shares gain 5% after USFDA okays capsules; m-cap rises by Rs 3,021 cr

The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.

v
Premium

The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.

Press Trust of India Mumbai
Shares of drug firm Cipla on Friday gained over 5 per cent after the company said it has received the final approval from the US health regulator for Dimethyl Fumarate capsules.

The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.

On the NSE, it gained 4.99 per cent to settle at Rs 770.10.

The company's market valuation also rose by Rs 3,021.11 crore to Rs 62,104.11 crore.

The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.

Cipla

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in